Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05881564 · ClinicalTrials.gov registry record · NA
Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery
A NA study of Congenital Heart Disease, sponsored by Augusta University.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05881564: Recruiting NA study of Congenital Heart Disease, sponsored by Augusta University.
NCT05881564 is a NA study of Congenital Heart Disease that is actively recruiting participants, run by Augusta University. The registered enrollment target is 150 participants, below the 472-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05881564, a NA study of Congenital Heart Disease, is actively recruiting participants, sponsored by Augusta University.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate if there is any clinical difference in patients 3.5-12kg who undergo cardiac surgery with cardiopulmonary bypass that do and do not receive blood products as part of their procedure. The main hypothesis of the study is that the patients undergoing bloodless cardiac surgery will have decreased morbidity and mortality when compared to the cohort that did receive blood as well as a shorter ICU and hospital length of stay.
Conditions Studied
Interventions
- OTHER blood use for priming cardiopulmonary bypass circuit
- OTHER clear prime for cardiopulmonary bypass
Study Locations (1)
Georgia
- Children's Hospital of Georgia - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2026-05-12 |
| Phase | NA |
What NCT05881564 shows while recruiting
NCT05881564 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 472-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which blood use for priming cardiopulmonary bypass circuit is the first listed.
NCT05881564 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05881564 about?
NCT05881564 is a clinical study titled "Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery". To evaluate if there is any clinical difference in patients 3.5-12kg who undergo cardiac surgery with cardiopulmonary bypass that do and do not receive blood products as part of their procedure. The main hypothesis of the study is that the patients undergoing bloodless cardiac surgery will have decr...
What is the current status of trial NCT05881564?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2023-05-10. Estimated completion is 2026-05-12.
What conditions does trial NCT05881564 study?
This clinical trial studies the following conditions: Congenital Heart Disease.
What interventions are being tested in trial NCT05881564?
The interventions under investigation include: blood use for priming cardiopulmonary bypass circuit (OTHER), clear prime for cardiopulmonary bypass (OTHER).
Who is sponsoring clinical trial NCT05881564?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05881564 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05881564's enrollment target sits among peer trials
150 24th of 63 higher than 39 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study
RECRUITING · NA
-
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
RECRUITING · NA
-
A Study of Hemodynamic Cardiopulmonary Exercise for CHD
RECRUITING · NA
-
Ventripoint Single Ventricle Study
RECRUITING · NA
-
Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI